Generated Narrative: Citation 267246

url: Citation 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.

identifier: FEvIR Object Identifier/267246, https://pubmed.ncbi.nlm.nih.gov/11232013, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.44

version: 2.0.0-ballot

title: 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.

status: Active

date: 2024-11-01 10:20:00+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description:

UseContexts

jurisdiction: World

copyright:

approvalDate: 2001-04-12

lastReviewDate: 2018-11-30

author: Computable Publishing®: MEDLINE-to-FEvIR Converter:

classification

type: Citation Source

classifier: MEDLINE

classification

type: MEDLINE Citation Owner

classifier: National Library of Medicine, Index Section

currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish

statusDate

activity: PubMed Pubstatus of Pubmed

period: ?? --> 2001-03-07 10:00:00+0000

statusDate

activity: PubMed Pubstatus of Medline

period: ?? --> 2001-04-17 10:01:00+0000

statusDate

activity: PubMed Pubstatus of Entrez

period: ?? --> 2001-03-07 10:00:00+0000

citedArtifact

identifier: https://pubmed.ncbi.nlm.nih.gov/11232013, https://doi.org/10.1210/jcem.86.1.7157

Titles

-	Type	Language	Text
*	Primary title	English	Rosiglitazone monotherapy is effective in patients with type 2 diabetes.

Abstracts

-

Text

*

This study evaluated the efficacy and safety of rosiglitazone monotherapy in patients with type 2 diabetes. After a 4-week placebo run-in period, 493 patients with type 2 diabetes were randomized to receive rosiglitazone [2 or 4 mg twice daily (bd)] or placebo for 26 weeks. The primary end point was change in hemoglobin A(1c); other variables assessed included fasting plasma glucose, fructosamine, endogenous insulin secretion, urinary albumin excretion, serum lipids, and adverse events. Rosiglitazone (2 and 4 mg bd) decreased mean hemoglobin A(1c) relative to placebo by 1.2 and 1.5 percentage points, respectively, and reduced fasting plasma glucose concentrations relative to placebo by 3.22 and 4.22 mmol/L, respectively. Fasting plasma insulin and insulin precursor molecules decreased significantly. Homeostasis model assessment estimates indicate that rosiglitazone (2 and 4 mg bd) reduced insulin resistance by 16.0% and 24.6%, respectively, and improved ss-cell function over baseline by 49.5% and 60.0%, respectively. Urinary albumin excretion decreased significantly in the rosiglitazone (4 mg bd) group. There was no increase in adverse events with rosiglitazone. In the short-term, rosiglitazone is an insulin sensitizer that is effective and safe as monotherapy in patients with type 2 diabetes who are inadequately controlled by lifestyle interventions.

relatesTo

type: correction-in

classifier: Published Erratum

citation:

J Clin Endocrinol Metab 2001 Apr;86(4):1659

relatesTo

type: correction-in

classifier: Published Erratum

citation:

J Clin Endocrinol Metab. 2002 Feb;2(1):iv.

publicationForm

publishedIn

type: Periodical

identifier: Print ISSN Type/0021-972X, ISOAbbreviation/J Clin Endocrinol Metab, ISSN Linking/0021-972X, Medline Title Abbreviation/J Clin Endocrinol Metab, NLM Unique ID/0375362

title: The Journal of clinical endocrinology and metabolism

publisherLocation: United States

citedMedium: Print

volume: 86

issue: 1

articleDate: 2001-01

publicationDateText: 2001-Jan

language: English

pageString: 280-8

WebLocations

-	Classifier	Url
*	Abstract	https://pubmed.ncbi.nlm.nih.gov/11232013/

classification

type: Publishing Model

classifier: Print

classification

type: Chemical

classifier: Blood Glucose, Hypoglycemic Agents, Thiazoles, Thiazolidinediones, Rosiglitazone

classification

type: MeSH heading

artifactAssessment: ArtifactAssessment: artifact[x] = this resource

classification

type: Publication type

classifier: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial

classification

type: Knowledge Artifact Type

classifier: Journal Article

artifactAssessment: Classifier added by Computable Publishing LLC

classification

type: Citation subset

classifier: IM

contributorship

complete: true

entry

contributor: Lebovitz HE

forenameInitials: HE

affiliation: Department of Medicine, State University of New York, Brooklyn, New York 11203, USA. hlebovitz@attglobal.net

entry

contributor: Dole JF

forenameInitials: JF

entry

contributor: Patwardhan R

forenameInitials: R

entry

contributor: Rappaport EB

forenameInitials: EB

entry

contributor: Freed MI

forenameInitials: MI

entry

contributor: Rosiglitazone Clinical Trials Study Group

Generated Narrative: Practitioner #contributor0

name: H E Lebovitz

Generated Narrative: Practitioner #contributor1

name: J F Dole

Generated Narrative: Practitioner #contributor2

name: R Patwardhan

Generated Narrative: Practitioner #contributor3

name: E B Rappaport

Generated Narrative: Practitioner #contributor4

name: M I Freed

Generated Narrative: Organization #contributor5

name: Rosiglitazone Clinical Trials Study Group

Generated Narrative: ArtifactAssessment #meshHeading0

artifact: Citation 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Aged

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Aged, 80 and over

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Blood Glucose

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: analysis

Components

-	Type	Classifier
*	is Major topic	No

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Diabetes Mellitus, Type 2

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: blood

Components

-	Type	Classifier
*	is Major topic	No

component

type: qualifier

classifier: drug therapy

Components

-	Type	Classifier
*	is Major topic	Yes

component

type: qualifier

classifier: physiopathology

Components

-	Type	Classifier
*	is Major topic	No

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Double-Blind Method

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Female

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Humans

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Hypoglycemic Agents

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: adverse effects

Components

-	Type	Classifier
*	is Major topic	No

component

type: qualifier

classifier: therapeutic use

Components

-	Type	Classifier
*	is Major topic	Yes

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Islets of Langerhans

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: drug effects

Components

-	Type	Classifier
*	is Major topic	No

component

type: qualifier

classifier: physiopathology

Components

-	Type	Classifier
*	is Major topic	No

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Male

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Middle Aged

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Rosiglitazone

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Single-Blind Method

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Thiazoles

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: adverse effects

Components

-	Type	Classifier
*	is Major topic	No

component

type: qualifier

classifier: therapeutic use

Components

-	Type	Classifier
*	is Major topic	Yes

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Thiazolidinediones

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is Major topic